Theragnostics in Austria

Over the past decades, Professor Kalevi Kairemo has been a well-known and dear colleague with whom we have excellently cooperated, especially via the international organisations IAEA (International Atomic Energy Agency) and The WARMTH (World Association of Radiopharmaceutical and Molecular Therapy). The work resulted in the construction of radiotracers using different modal systems, including a variety of radiolabelled peptide analogues such as somatostatin, cholecystokinin (CCK-2/gastrin), or prostate-specific membrane antigen (PSMA) ligand for specific tumour targeting. Radiopharmaceuticals are produced at clinical grade in dedicated laboratories for use in SPECT/CT or PET/CT studies. Patients evaluated by SPECT/CT dosimetry studies are treated with high dose thera(g)nostics. Radioiodine ablation therapy of thyroid cancer remnants, peptide receptor radionuclide therapy (PRRT) of NET patients, and peptide ligand radionuclide therapy (PLRT) of PC patients are today the most important therapeutic tools.